If that goes well, injection trials will start in October.Not everywhere is blessed with basalt, of course.
Injection trials were videotaped.
Each run contained 12 blocks, with each block consisting of either five numbed hand or five injection trials.
We therefore correlated the signal difference between numbed hand and injection trials (numbed>non-numbed, intensity trials only) with the difference in intensity ratings for numbed and non-numbed stimuli.
Based on initial injection trials, 0.5 µg/µl (about 60 µM), was chosen as the optimal concentration for rps3, rps3a, rps4, rps8, rps15, rps15a, rps19, rpl6, rpl11, rpl24, rpl35, rpl35a, rpl36a, and rpl38, whereas 5.0 µg/µl (about 0.6 mM) was considered optimal for rps29, rpl5 (both copies), rpl28, rplp0, rplp1, and rplp2.
Morpholino injection trials with greater than 25% lethality at 24 hpf were discarded, and the morpholino dose was adjusted to reduce lethality.
Based on the literature and our initial injection trials, 0.5-ng Rpl11 MO and control MO were chosen as the optimal concentration.
However, the lack of cytotoxicity observed does not preclude the possibility that some damage to muscle occurs immediately after injection, resulting in some level of degeneration-regeneration. This process may underlie to some extent the high number of dystrophin-positive fibers observed in our 6 week (10 injection) trials.
Spontaneous walking was measured as the total duration of exploration of the arena during a 10-min (after procaine injections) or a 30-min (after venom injections) trial period.
